AIM Vaccine(HKG:6660) wholly-owned subsidiary, AIM Rongyu (Ningbo) Biopharmaceutical, will submit an application for drug marketing registration after obtaining the production license for the iterative serum-free rabies vaccine, according to a Wednesday filing with the Hong Kong bourse.
The vaccine earlier underwent Phase III clinical trials and could meet the preset goals, the filing added.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。